With the approval of immune checkpoint blockade for the treatment of breast cancer (46), it may be worthwhile to explore whether anti-OAcGD2 may also enhance the anticancer efficacy of anti-PD1/PD-L1 in breast cancer. Here, CD274 is linked to breast cancer.